Charlie Gayer: I think we — what we would see is that patients who — kids that need to start on prophylaxis and oral is going to be the best option for them just for obvious reasons. And this is a lifelong disease. So we think there’s an opportunity for these kids to be on ORLADEYO for a very long period of time. And then as I mentioned earlier, just the family aspect of it too as a genetic disease. Usually, there is a parent or often a sibling, other family members in the household. And so it’s an opportunity for whole families to become more aware of the benefits of ORLADEYO. So we would expect them to stay on for the long term.
Francois Brisebois: Understood. Thank you.
Operator: The next question comes from Jon Wolleben with JMP Securities. Please go ahead.
Jon Wolleben: Hey, thanks for taking the question. One on your market research, which has been seemingly accurate in the past. When you ask about prescribing in the next 12 months, wondering if you actually ask longer term as well about ultimate usage, how that factors into your growth projection? Then also, it seems to be reflective of the uptake we’re seeing. Do you ever have to expand who you’re asking and what you’re asking about to get more insight into what the trajectory looks like three, four years down the line?
Charlie Gayer: Yeah. Thanks for the question, Jon. We absolutely do look at that longer term and ask them about the longer term. The growth in the next 12 months, that’s the quarterly survey that we do with 60 to 100 physicians every quarter. Then we use that information plus other studies once a year to build a much longer-term model where we also incorporate everything that might come in the future, and we ask physicians, their opinions of those products, what they think they will use. And then that all goes into a much larger market forecasting model to predict the future. It was very accurate in our first year of launch. And every year, our team updates this model. And so we have a lot of confidence in our future predictions. And it is — that is where our $1 billion peak revenue comes from. It comes from that model that incorporates all of the forward-looking market research.
Jon Wolleben: And then when this year, do you guys do that annual revamp? And do you — will you guys let us know the results?
Charlie Gayer: We will let you know if anything changes. We do it once a year around the middle of the year. And yeah, we — our goal is to be accurate in all of our forecasting. So if we see anything different, we’ll definitely let you know.
Jon Wolleben: Got it. Thanks, Charlie.
Operator: Your last question comes from Chris Raymond with Piper Sandler. Please go ahead.
Chris Raymond: Thanks for squeezing me in. Jon, you’ve been pretty open in the past when folks have asked you guys about strategic interest and sort of inbound interest. And I think it’s pretty clear now — by now that there’s a lot of buoyancy here, if you will, for maybe lack of a better word to ORLADEYO’s uptake. I guess any discernible change in terms of frequency or maybe tenor of the inbound calls that you guys have had from strategics? Thanks.
Jon Stonehouse: Yeah, Chris, I mean, you know I can’t talk about specifics and volume or changes. But the answer about our willingness to entertain those remains unchanged. We’re a public company, and we have shareholder interest in our minds. And if someone is interested, we’ll take the call. So no change there.
Chris Raymond: Thank you.
Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Jon Stonehouse for any closing remarks.
Jon Stonehouse: Yeah. Thanks again for your interest in our company. We are off to a really, really good start to this year, and we’re super excited about where this will lead us to in terms of ORLADEYO trajectory and advancing the pipeline. So we’re focused on continuing this momentum throughout the year and look forward to updating you as we have new information. Have a great day.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
